Eisai Co., Ltd. (OTCPK:ESALF) Q3 2024 Earnings Name Transcript February 7, 2025 1:00 AM ET
Firm Individuals
Haruo Naito – Consultant Company Officer & CEO
Terushige Iike – Government Vice President, Chief Technique and Planning Officer
Katsuya Haruna – Group Officer & Government Vice President, U.S. Enterprise Operations
Kazuhiko Tamura – Vice President, Eisai Demand Chain Methods
Lynn Kramer – Vice President, Chief Scientific Officer
Takashi Owa – Senior Vice President Chief Scientific Officer Japan Medical Security
Tomo Ogawa – Division Supervisor, Scientific Operations
Convention Name Individuals
Hidemaru Yamaguchi – Citigroup
Seiji Wakao – JPMorgan
Takashi Akahane – Tokai Tokyo
Miki Sogi – Bernstein
Shinichiro Muraoka – Morgan Stanley
Kazuaki Hashiguchi – Daiwa Securities
Hinako Banno – Nikkei Newspaper
Yuki Osanai – Yomiuri Shimbun
Operator
Thanks very a lot for taking your trip of your busy schedule to attend the Monetary Outcomes and Enterprise Replace Presentation for Q3 Fiscal 2024 by Eisai Firm Restricted. That is carried out in hybrid format together with in-person attendance and digital attendance. These of you who’re attending in particular person, please discover supplies together with presentation deck, a quick report. For these of you who’re collaborating just about, please obtain these supplies or examine the supplies on-line. Let me introduce the presenter at this time, Mr. Keisuke Naito, Consultant Company Officer, Government Vice President, COO, and Chief Progress Officer. CEO, Mr. Naito, please have the ground.
Haruo Naito
Sure. Thanks very a lot. Now I wish to report on the monetary outcomes for the third quarter of fiscal yr 2024. That is at this time’s agenda. Subsequent slide, please. As for the consolidated enterprise outcomes for the third quarter of FY 2024, the pharmaceutical continued to make regular progress with a rise in income and double-digit revenue progress from the earlier yr. Income was 601.2 billion yen, up 9% year-on-year and up 49.9 billion yen from the earlier yr. Income
